Clinical Trials
55 results for Prostate Cancer
1-50 of 55 Next
Prospective Evaluation of CyberKnife® as Monotherapy or Boost Stereotactic Body Radiotherapy for Intermediate or High Risk Localized Prostate Cancer
- Condition: Prostate Adenocarcinoma
- Intervention: Radiation: CyberKnife, Other: Androgen Deprivation Therapy (ADT), Radiation: Intensity Modulated radiation therapy (IMRT)
- Study ID: NCT01985828
Evaluation of the TULSA-PRO MRI-guided Transurethral Ultrasound Prostate Ablation Device in Patients With Localized Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Device: MRI-guided Transurethral Ultrasound Ablation
- Study ID: NCT02766543
The UCLA ASCAP Project is an Observational, Longitudinal, and Open-ended Study Aimed at Establishing a Structured Program of Non-interventional Follow-up for Localized Prostate Cancer.
- Condition: Prostate Cancer
- Intervention: Other: Active surveillance
- Study ID: NCT00949819
Prospective Evaluation of CyberKnife Stereotactic Body Radiotherapy for Localized Prostate Cancer: Risk Stratified Monotherapy Versus Boost
- Condition: Prostate Cancer
- Intervention:
- Study ID: NCT02016248
Primary Radical Prostatectomy Versus Primary Radiotherapy for Locally Advanced Prostate Cancer: an Open Randomized Clinical Trial
- Condition: Prostatic Neoplasms
- Intervention: Procedure: Prostatectomy/Surgery, Other: Radiotherapy with adjuvant androgen deprivation therapy
- Study ID: NCT02102477
Focal Low Dose Rate ( LDR) Brachytherapy: Hemi-ablative Treatment With LDR for Patients With Low and Low-tier Intermediate Risk Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Radiation: Transperineal template guided mapping biopsy, multiparametric MRI, Hemiablative Focal Brachytherapy
- Study ID: NCT02643511
Safety and Early Efficacy of Radical Prostatectomy for Newly Diagnosed Very High Risk Locally Advanced and Oligometastatic Prostate Cancer - a Prospective Single Center Phase I/II Study
- Condition: Locally Advanced and Metastatic Prostate Cancer
- Intervention: Procedure: Radical prostatectomy
- Study ID: NCT02971358
Phase III Study of Image Guided Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Adenocarcinoma of the Prostate
- Condition: Prostate Cancer
- Intervention: Radiation: Radiation, Drug: Androgen Suppression Therapy
- Study ID: NCT01492972
A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin in Reducing Progression Among Men on Expectant Management for Low Risk Prostate Cancer: The MAST (Metformin Active Surveillance Trial) Study
- Condition: Prostate Cancer
- Intervention: Drug: Metformin, Drug: Placebo
- Study ID: NCT01864096
Phase I-II Study HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer With or Without Metastatic Disease
- Condition: Prostatic Neoplasms
- Intervention: Drug: HSV-tk +Valacyclovir in Combination with Brachytherapy
- Study ID: NCT01913106
MRI-Guided HDR Brachytherapy for Prostate Cancer
- Condition: Patients With Prostate Cancer
- Intervention: Procedure: MRI Guided Needles to deliver HDR Brachytherapy, Procedure: MRI Guided Needles to deliver HDR Brachytherapy
- Study ID: NCT00913939
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
- Condition: Breast Cancer, Bladder Cancer, Kidney Cancer, Colon Cancer, Prostate Cancer, Lung Cancer, Ovarian Cancer
- Intervention: Genetic: PCR/PCR/LDR Strategy
- Study ID: NCT00579514
Collection of Blood From Patients With Prostate Cancer
- Condition: Prostatic Neoplasms
- Study ID: NCT00923221
Canary Prostate Active Surveillance Study
- Condition: Prostatic Neoplasms
- Study ID: NCT00756665
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Drug: [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone
- Study ID: NCT00588185
A Pilot Study of High Dose Rate Brachytherapy in The Radiation Oncology Branch
- Condition: Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Prostate Cancer, Biliary Cancer
- Intervention: Radiation: Brachytherapy
- Study ID: NCT00924027
A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration Resistant Prostate Cancer Patients Metastatic to Bone.
- Condition: Prostate Cancer
- Intervention: Drug: Ra223, Drug: Enzalutamide
- Study ID: NCT02194842
Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene and Characterization of the Predisposition to Renal Cancer
- Condition: Renal Tumor Histology, Cutaneous Leiomyomatosis, Kidney Cancer
- Study ID: NCT00050752
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
- Condition: Malignant Neoplasms, Hereditary Neoplastic Syndromes, Kidney Cancer, Renal Cancer
- Study ID: NCT00026884
A Phase III Randomized Trial of MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial
- Condition: Prostate Cancer, Prostate Adenocarcinoma
- Intervention: Radiation: Standard Salvage Radiation Treatment (SSRT), Radiation: Mapped Tumor Salvage RT (MTSRT), Behavioral: Expanded Prostate Cancer Index Composite-SF12, Behavioral: Memory Anxiety Scale for Prostate Cancer patients, Behavioral: International Prostate Symptom Score (IPSS)
- Study ID: NCT01411345
Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy
- Condition: Prostate Cancer
- Intervention: Radiation: IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE, Radiation: Proton (prostate bed) to 70.2 CGE, Radiation: IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE, Radiation: Proton to 66.6 CGE
- Study ID: NCT00969111
A Randomized Trial of Modifications to Radical Prostatectomy
- Condition: Prostate Cancer
- Intervention: Procedure: Lymph node template, Procedure: Transverse versus vertical closure, Drug: antibiotic prophylaxis
- Study ID: NCT01407263
Collection of Blood From Patients With Cancer for Analysis of Genetic Differences in Drug Disposition
- Condition: Prostate Cancer, Breast Cancer, Lung Cancer, Ovarian Cancer, Lymphoma
- Study ID: NCT01441089
Biospecimen Acquisition From Human Subjects
- Condition: Prostate Cancer, Breast Cancer, Colon Cancer, Lung Cancer, Liver Cancer
- Intervention:
- Study ID: NCT00034216
Carbon Ion Radiotherapy for the Treatment of Localized Prostate Cancer
- Condition: Prostate Carcinoma
- Intervention:
- Study ID: NCT02739659
Phase I/II Study of PROSTVAC in Combination With Nivolumab and / or Ipilimumab in Men With Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Biological: PROSTVAC-V/F, Drug: Nivolumab, Drug: Ipilimumab
- Study ID: NCT02933255
HDR Monotherapy for Prostate Cancer: A Feasibility Study of Focal Radiotherapy Yields
- Condition: Prostate Cancer
- Intervention: Radiation: targeted focal HDR brachytherapy, Radiation: Whole-gland HDR Brachytherapy
- Study ID: NCT02918253
Phase II Study of Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
- Condition: Prostate
- Intervention: Drug: Olaparib
- Study ID: NCT03047135
Phase II Study: [18F]DCFPyL PET/MRI for Personalizing Prostate Cancer Subclinical Metastatic Ablative MR-guided Radiotherapy (MRgRT)
- Condition: Post Prostatectomy
- Intervention: Diagnostic Test: [18F]DCFPyL PET/MRI scan, Radiation: Stereotactic Ablative Radiotherapy
- Study ID: NCT03160794
Fluorine-18 - 2-(3-(1-carboxy-5-[(6-[18F]Fluoro-pyridine-3-carbonyl)-Amino]-Pentyl)-Ureido)-Pentanedioic Acid (18F-DCFPyL) Positron Emission Tomography / Computed Tomography (PET/CT) for Assessment of Recurrent Prostate Cancer
- Condition: Prostatic Neoplasms, Prostate Cancer
- Intervention: Drug: PSMA PET/CT scan
- Study ID: NCT02899312
Diagnosing Clinically Significant Prostate Cancer in African American and White Men Phase II, Randomized Clinical Trial, Multi-center, MR-Guided vs. 12-core Systematic Random Biopsy, Localized Prostate Cancer
- Condition: Health Status Unknown, PSA Progression
- Intervention: Procedure: Biopsy of Prostate, Other: Laboratory Biomarker Analysis, Diagnostic Test: Magnetic Resonance Imaging, Diagnostic Test: MRI Ultrasound Fusion Guided Biopsy
- Study ID: NCT03234556
Phase I Feasibility Trial of Stereotactic Re-irradiation of Prostate Cancer Recurrence Within the Definitively Irradiated Prostate
- Condition: Locally Recurrent Prostate Cancer
- Intervention: Radiation: Stereotactic Body Radiotherapy
- Study ID: NCT03073278
The Role of Androgen Deprivation Therapy In Cardiovascular Disease - A Longitudinal Prostate Cancer Study (RADICAL PC1) & A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICAL PC2)
- Condition: Prostate Cancer, Cardiovascular Disease
- Intervention:
- Study ID: NCT03127631
PHASE I STUDY OF PSMA-TGFβRDN CAR MODIFIED T CELLS IN PATIENTS WITH ADVANCED CASTRATE RESISTANT PROSTATE CANCER
- Condition: Prostate Cancer
- Intervention:
- Study ID: NCT03089203
A Feasibility and Safety Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) in Subjects With Non-Resectable Pancreatic Cancer
- Condition: Non-Resectable Pancreatic Cancer
- Intervention: Biological: BPX-601, Drug: Rimiducid
- Study ID: NCT02744287
Cystoprostatectomy Versus Radiotherapy Combined With Androgen Deprivation Therapy for the Treatment of Clinical T4 Prostate Cancer With Bladder Invasion: a Multicentre, Prospective, Open, Randomized Clinical Trial
- Condition: Prostate Cancer
- Intervention: Procedure: Cystoprostatectomy, Radiation: external beam radiotherapy
- Study ID: NCT03482089
Quality of Life in Patients With Clinically Localized Prostate Cancer Treated With Stereotactic Body Radiation Therapy (SBRT)
- Condition: Prostate Cancer, Localized Malignant Neoplasm
- Intervention: Radiation: Stereotactic Body Radiation Therapy (SBRT)
- Study ID: NCT01766492
A Randomized Clinical Trial of Exercise vs. Usual Care Among Men Opting for Active Surveillance for Prostate Cancer
- Condition: Localized Prostate Cancer, Active Surveillance for Prostate Cancer
- Intervention: Behavioral: Exercise
- Study ID: NCT02435472
Open-label Clinical Study to Assess the Safety and Adequacy of Effectiveness of the SpectraCure P18 System (Interstitial Multiple Diode Lasers and IDOSE® Software) and Verteporfin for Injection (VFI) for the Treatment of Recurrent Prostate Cancer
- Condition: Recurrent Prostate Cancer
- Intervention:
- Study ID: NCT03067051
Phase Ib Trial of Pembrolizumab (MK-3475) With Platinum-Based Chemotherapy in Small Cell/Neuroendocrine Cancers of Urothelium and Prostate
- Condition: Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Prostate Carcinoma Metastatic in the Bone, Prostate Neuroendocrine Neoplasm, Pro
- Intervention: Drug: Carboplatin, Drug: Cisplatin, Drug: Docetaxel, Drug: Etoposide, Biological: Pembrolizumab
- Study ID: NCT03582475
Phase II Study of Neoadjuvant Pembrolizumab Plus Intensive Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Drug: Pembrolizumab, Drug: Enzalutamide
- Study ID: NCT03753243
Phase 2, Multicenter, Prospective Cohort Study, Estimating the Efficacy of Focused HIFU Therapy in Patients With Localized Intermediate Risk Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Procedure: treatment with focal HIFU, Biological: PSA dosage, Device: MRI, Other: Questionnaires, Procedure: Prostatic biopsies, Biological: blood test, Biological: urine test
- Study ID: NCT03568188
A Randomized Pilot Study Comparing High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy in Localized Prostate Cancer
- Condition: Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
- Intervention: Radiation: High-Dose Rate Brachytherapy, Other: Quality-of-Life Assessment, Other: Questionnaire Administration, Procedure: Stereotactic Ablative Radiotherapy
- Study ID: NCT04253483
PSMA-PET Registry for Recurrent Prostate Cancer Following Radical Prostatectomy
- Condition: Recurrent Prostate Cancer
- Intervention: Diagnostic Test: [18F]-DCFPyL PET/ CT scan (PSMA PET)
- Study ID: NCT03718260
Hypofractionated Radiosurgery for Localised Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Radiation: Hypofractionated Radiosurgery
- Study ID: NCT03795337
Darolutamide Observational Study in Non-metastatic Castration-resistant Prostate Cancer Patients
- Condition: Prostate Cancer
- Intervention: Drug: Darolutamide(Nubeqa, BAY1841788)
- Study ID: NCT04122976
DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801): A Randomised Phase 3 Double-blind, Placebo-controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvag
- Condition: Prostate Cancer
- Intervention: Drug: Darolutamide, Drug: Placebo oral tablet, Drug: Luteinizing Hormone-Releasing Hormone Analog, Radiation: External Beam Radiotherapy
- Study ID: NCT04136353
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
- Condition: Prostatic Neoplasms
- Intervention: Drug: Apalutamide, Drug: Androgen Deprivation Therapy (ADT), Drug: Placebo
- Study ID: NCT03767244
Phase 3, Multicenter, Randomized Study, Evaluating the Efficacy and Tolerability of Focused HIFU Therapy Compared to Active Surveillance in Patients With Significant Low Risk Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Procedure: treatment with focal HIFU, Biological: PSA dosage, Device: MRI, Other: Questionnaires, Procedure: Prostatic biopsies
- Study ID: NCT03531099
Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy in the Management of Gleason Group 5 Prostate Cancer
- Condition: Prostate Cancer, Prostate Disease
- Intervention: Drug: Nivolumab, Radiation: Brachytherapy, Radiation: External Beam Radiation Therapy, Drug: Androgen Deprivation Therapy
- Study ID: NCT03543189